Return
Ustekinumab
DOI:10.1038/nrd2878.png)
Abstract
En
Keywords:
INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY
PLAQUE-TYPE PSORIASIS
QUALITY-OF-LIFE
DOUBLE-BLIND
SKIN
EFFICACY
SAFETY
TRIAL
METAANALYSIS
EXPRESSION
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
101.8
Papers:
5.1K
Citations:
5.3W
Organization
Cited Papers
Disease severity, quality of life and health care in plaque-type psoriasis:: A multicenter cross-sectional study in Germany
DERMATOLOGY
IF2.7
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
LANCET
IF88.5
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
LANCET
IF88.5

